EGFR signaling defines Mcl^-1 survival dependency in neuroblastoma

References

• Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009; 27:1007-13; PMID:19171716; http://dx.doi.org/10.1200/JCO.2007.13.8925
   PubMed Web of Science ®Google Scholar
• Goldsmith KC, Hogarty MD. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 2005; PMID:15927359
   PubMed Web of Science ®Google Scholar
• Walensky LD. BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 2006; 13:1339-50; PMID:16763614; http://dx.doi.org/10.1038/sj.cdd.4401992
   PubMed Web of Science ®Google Scholar
• Goldsmith KC, Gross M, Peirce S, Luyindula D, Liu X, Vu A, Sliozberg M, Guo R, Zhao H, Reynolds CP, et al. Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res 2012; 72:2565-77; PMID:22589275; http://dx.doi.org/10.1158/0008-5472.CAN-11-3603
   PubMed Web of Science ®Google Scholar
• Goldsmith KC, Lestini BJ, Gross M, Ip L, Bhumbla A, Zhang X, Zhao H, Liu X, Hogarty MD. BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death Differ 2010; 17:872-82; PMID:19893570; http://dx.doi.org/10.1038/cdd.2009.171
   PubMed Web of Science ®Google Scholar
• Lestini BJ, Goldsmith KC, Fluchel MN, Liu X, Chen NL, Goyal B, Pawel BR, Hogarty MD. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009; 8; PMID:19556859
   PubMed Web of Science ®Google Scholar
• Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007; 67:782-91; PMID:17234790; http://dx.doi.org/10.1158/0008-5472.CAN-06-3964
   PubMed Web of Science ®Google Scholar
• van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10:389-99; PMID:17097561; http://dx.doi.org/10.1016/j.ccr.2006.08.027
   PubMed Web of Science ®Google Scholar
• Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE. Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 2009; 7:549-56; PMID:19372583; http://dx.doi.org/10.1158/1541-7786.MCR-08-0358
   PubMed Web of Science ®Google Scholar
• Jourdan M, De Vos J, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-α and insulin-like growth factor 1. Cell Death Differ 2000; 7:1244-52; PMID:11175262; http://dx.doi.org/10.1038/sj.cdd.4400758
   PubMed Web of Science ®Google Scholar
• Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A, Maris J, Evans AE, Brodeur GM. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 2005; 65:9868-75; PMID:16267010; http://dx.doi.org/10.1158/0008-5472.CAN-04-2426
   PubMed Web of Science ®Google Scholar
• Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Current cancer drug targets 2009; 9:729-37; PMID:19754357; http://dx.doi.org/10.2174/156800909789271521
   PubMed Web of Science ®Google Scholar
• Meyers MB, Shen WP, Spengler BA, Ciccarone V, O'Brien JP, Donner DB, Furth ME, Biedler JL. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 1988; 38:87-97; PMID:2464605; http://dx.doi.org/10.1002/jcb.240380203
   PubMed Web of Science ®Google Scholar
• Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 2007; 67:735-45; PMID:17234785; http://dx.doi.org/10.1158/0008-5472.CAN-06-2201
   PubMed Web of Science ®Google Scholar
• Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 2001; 61:8-13; PMID:11196202
   PubMed Web of Science ®Google Scholar
• Zhai D, Jin C, Huang Z, Satterthwait AC, Reed JC. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem 2008; 283:9580-6; PMID:18178565; http://dx.doi.org/10.1074/jbc.M708426200
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-11; PMID:15329413; http://dx.doi.org/10.1073/pnas.0405220101
   PubMed Web of Science ®Google Scholar
• Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2:183-92; PMID:12242151; http://dx.doi.org/10.1016/S1535-6108(02)00127-7
   PubMed Web of Science ®Google Scholar
• Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, Kaufman JL, Lee KP, Lonial S, Boise LH. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 2011; 118:1329-39; PMID:21659544; http://dx.doi.org/10.1182/blood-2011-01-327197
   PubMed Web of Science ®Google Scholar
• Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003; 278:18811-6; PMID:12646560; http://dx.doi.org/10.1074/jbc.M301010200
   PubMed Web of Science ®Google Scholar
• Ley R, Ewings KE, Hadfield K, Howes E, Balmanno K, Cook SJ. Extracellular signal-regulated kinases 1/2 are serum-stimulated “Bim(EL) kinases7rdquo; that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem 2004; 279:8837-47; PMID:14681225; http://dx.doi.org/10.1074/jbc.M311578200
   PubMed Web of Science ®Google Scholar
• Mouhamad S, Besnault L, Auffredou MT, Leprince C, Bourgeade MF, Leca G, Vazquez A. B cell receptor-mediated apoptosis of human lymphocytes is associated with a new regulatory pathway of Bim isoform expression. J Immunol 2004; 172:2084-91; PMID:14764673; http://dx.doi.org/10.4049/jimmunol.172.4.2084
   PubMedGoogle Scholar
• Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013; 45(3):279-84; PMID:23334666; http://dx.doi.org/10.1038/ng.2529. Epub 2013 Jan 20
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol 2008; 26:4921-7; PMID:18794549; http://dx.doi.org/10.1200/JCO.2007.15.2306
   PubMed Web of Science ®Google Scholar
• Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Croop JM, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2005; 23:6172-80; PMID:16135484; http://dx.doi.org/10.1200/JCO.2005.11.429
   PubMed Web of Science ®Google Scholar
• Cao X, Zhu H, Ali-Osman F, Lo HW. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis. Molecular cancer 2011; 10:26; PMID:21388543; http://dx.doi.org/10.1186/1476-4598-10-26
   PubMed Web of Science ®Google Scholar
• Zhu H, Cao X, Ali-Osman F, Keir S, Lo HW. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer Lett 2010; 294:101-10; PMID:20153921; http://dx.doi.org/10.1016/j.canlet.2010.01.028
   PubMed Web of Science ®Google Scholar
• Rizzatti EG, Mora-Jensen H, Weniger MA, Gibellini F, Lee E, Daibata M, Lai R, Wiestner A. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leuk Lymphoma 2008; 49:798-808; PMID:18398749; http://dx.doi.org/10.1080/10428190801910912
   PubMed Web of Science ®Google Scholar
• Chen S, Dai Y, Pei XY, Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 2009; 29:6149-69; PMID:19805519; http://dx.doi.org/10.1128/MCB.01481-08
   PubMed Web of Science ®Google Scholar
• Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 2009; 8:3173-80; PMID:19934277; http://dx.doi.org/10.1158/1535-7163.MCT-09-0685
   PubMed Web of Science ®Google Scholar
• Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 1970; 30:2110-8; PMID:5459762
   PubMed Web of Science ®Google Scholar
• Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG. Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 1986; 76:375-87; PMID:3456456
   PubMed Web of Science ®Google Scholar
• Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent JM. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305:245-8; PMID:6888561; http://dx.doi.org/10.1038/305245a0
   PubMed Web of Science ®Google Scholar
• Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58:5396-405; PMID:9850071
   PubMed Web of Science ®Google Scholar